Cargando…
PSMA PET imaging in the diagnosis and management of prostate cancer
Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. Imaging techniques such as CT, MRI, and bone scans have traditionally been used for diagnosis and staging. Molecular imaging modalities targeting the prostate-specific membrane antigen (PSMA) have recen...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682054/ https://www.ncbi.nlm.nih.gov/pubmed/37493837 http://dx.doi.org/10.1007/s00261-023-04002-z |
_version_ | 1785150894680047616 |
---|---|
author | Houshmand, Sina Lawhn-Heath, Courtney Behr, Spencer |
author_facet | Houshmand, Sina Lawhn-Heath, Courtney Behr, Spencer |
author_sort | Houshmand, Sina |
collection | PubMed |
description | Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. Imaging techniques such as CT, MRI, and bone scans have traditionally been used for diagnosis and staging. Molecular imaging modalities targeting the prostate-specific membrane antigen (PSMA) have recently gained attention due to their high affinity and accuracy. PSMA PET has been combined with other modalities such as multiparametric MRI for better diagnostic and prognostic performance. PSMA imaging has been studied at different clinical settings with a wide range of disease aggressiveness. In this review we will explore the role of PSMA PET in high-risk prostate cancer staging, biochemical recurrence, and castration-resistant prostate cancer. The primary focus of this review article is to examine the latest developments in the use of PSMA imaging and emphasize the clinical situations where its effectiveness has been demonstrated to significantly impact the treatment of prostate cancer. In addition, we will touch upon the potential future advancements of PSMA PET imaging and its evolving significance in the management of prostate cancer. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-10682054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-106820542023-11-30 PSMA PET imaging in the diagnosis and management of prostate cancer Houshmand, Sina Lawhn-Heath, Courtney Behr, Spencer Abdom Radiol (NY) Special Section: PET/MR Prostate cancer is the second leading cause of cancer-related deaths in men in the United States. Imaging techniques such as CT, MRI, and bone scans have traditionally been used for diagnosis and staging. Molecular imaging modalities targeting the prostate-specific membrane antigen (PSMA) have recently gained attention due to their high affinity and accuracy. PSMA PET has been combined with other modalities such as multiparametric MRI for better diagnostic and prognostic performance. PSMA imaging has been studied at different clinical settings with a wide range of disease aggressiveness. In this review we will explore the role of PSMA PET in high-risk prostate cancer staging, biochemical recurrence, and castration-resistant prostate cancer. The primary focus of this review article is to examine the latest developments in the use of PSMA imaging and emphasize the clinical situations where its effectiveness has been demonstrated to significantly impact the treatment of prostate cancer. In addition, we will touch upon the potential future advancements of PSMA PET imaging and its evolving significance in the management of prostate cancer. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2023-07-26 2023 /pmc/articles/PMC10682054/ /pubmed/37493837 http://dx.doi.org/10.1007/s00261-023-04002-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Special Section: PET/MR Houshmand, Sina Lawhn-Heath, Courtney Behr, Spencer PSMA PET imaging in the diagnosis and management of prostate cancer |
title | PSMA PET imaging in the diagnosis and management of prostate cancer |
title_full | PSMA PET imaging in the diagnosis and management of prostate cancer |
title_fullStr | PSMA PET imaging in the diagnosis and management of prostate cancer |
title_full_unstemmed | PSMA PET imaging in the diagnosis and management of prostate cancer |
title_short | PSMA PET imaging in the diagnosis and management of prostate cancer |
title_sort | psma pet imaging in the diagnosis and management of prostate cancer |
topic | Special Section: PET/MR |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10682054/ https://www.ncbi.nlm.nih.gov/pubmed/37493837 http://dx.doi.org/10.1007/s00261-023-04002-z |
work_keys_str_mv | AT houshmandsina psmapetimaginginthediagnosisandmanagementofprostatecancer AT lawhnheathcourtney psmapetimaginginthediagnosisandmanagementofprostatecancer AT behrspencer psmapetimaginginthediagnosisandmanagementofprostatecancer |